Equity Overview
Price & Market Data
Price: $0.106
Daily Change: +$0.0088 / 8.28%
Range: $0.106 - $0.106
Market Cap: $4,742,868
Volume: 4,000
Performance Metrics
1 Week: 23.57%
1 Month: 92.31%
3 Months: 2.48%
6 Months: 36.55%
1 Year: 18.25%
YTD: -11.96%
Details
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety, ADHD, non-neurological conditions of cancer, and non-alcoholic steatohepatitis. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.